Literature DB >> 20578237

Sickle cell anemia and vascular dysfunction: the nitric oxide connection.

Idowu Akinsheye1, Elizabeth S Klings.   

Abstract

Endothelial dysfunction and impaired nitric oxide bioavailability have been implicated in the pathogenesis of sickle cell anemia. Nitric oxide is a diatomic gas with a role in vascular homeostasis. Hemoglobin polymerization resulting from the HbS mutation produces erythrocyte deformation and hemolysis. Free hemoglobin, released into plasma by hemolysis scavenges on nitric oxide, and leads to reduced nitric oxide bioavailability. Pulmonary hypertension is a known consequence of sickle cell anemia. It occurs in 30-40% of patients with sickle cell anemia, and is associated with increased mortality. Several studies have implicated intravascular hemolysis, and impaired nitric oxide bioavailability in the pathogenesis of pulmonary hypertension. In this review, we summarize the mechanisms of altered nitric oxide bioavailability in sickle cell anemia and its possible role in the pathogenesis of pulmonary hypertension. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578237     DOI: 10.1002/jcp.22195

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  40 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Nitrergic Mechanisms for Management of Recurrent Priapism.

Authors:  Uzoma A Anele; Arthur L Burnett
Journal:  Sex Med Rev       Date:  2015-06-04

3.  Overactive bladder in adults with sickle cell disease.

Authors:  Uzoma A Anele; Belinda F Morrison; Marvin E Reid; Wendy Madden; Shara Foster; Arthur L Burnett
Journal:  Neurourol Urodyn       Date:  2015-04-14       Impact factor: 2.696

Review 4.  Thalassemia and Moyamoya syndrome: unfurling an intriguing association.

Authors:  Shambaditya Das; Souvik Dubey; Mrinal Acharya; Subhankar Chatterjee; Durjoy Lahiri; Goutam Das; Biman Kanti Ray; Markus Kraemer
Journal:  J Neurol       Date:  2019-08-17       Impact factor: 4.849

5.  Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.

Authors:  A M Omar; M A Mahran; M S Ghatge; N Chowdhury; F H A Bamane; M E El-Araby; O Abdulmalik; M K Safo
Journal:  Org Biomol Chem       Date:  2015-06-14       Impact factor: 3.876

6.  Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease.

Authors:  Emmanuil S Hatzipantelis; Zoe Dorothea Pana; N Gombakis; A Taparkou; V Tzimouli; D Kleta; D J Zafeiriou; V Garipidou; F Kanakoudi; M Athanassiou
Journal:  Int J Hematol       Date:  2013-06-27       Impact factor: 2.490

Review 7.  Interventions for treating intrahepatic cholestasis in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

8.  An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.

Authors:  Abdelsattar M Omar; Osheiza Abdulmalik; Mohini S Ghatge; Yosra A Muhammad; Steven D Paredes; Moustafa E El-Araby; Martin K Safo
Journal:  Biomolecules       Date:  2020-11-02

9.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

10.  Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.

Authors:  Guoyan G Xu; Piyusha P Pagare; Mohini S Ghatge; Ronni P Safo; Aheema Gazi; Qiukan Chen; Tanya David; Alhumaidi B Alabbas; Faik N Musayev; Jürgen Venitz; Yan Zhang; Martin K Safo; Osheiza Abdulmalik
Journal:  Mol Pharm       Date:  2017-09-13       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.